Dr. Boobalan Pachaiyappan
Recent Articles
Biotech Battles FDA, Target Price Shows Potential 90% Gains 10/01/2025
Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy.
Maryland Biotech Gains Regulatory Approval 12/26/2024
Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients.
Due to permission requirements, not all quotes are shown.
